Dynavax Technologies Inc. (NASDAQ: DVAX) stock gained by 7.57% at the last close while the DVAX stock price surges by 4.06% in the pre-market trading session. Dynavax is a biopharmaceutical firm in the commercial stage that is developing and commercializing new vaccines. HEPLISAV-B, the company’s first commercial medication, is authorized in the United States and the European Union for the prevention of hepatitis B virus infection characterized by all known subtypes in adults aged 18 and up.
DVAX stock’ Recent Development
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation have announced the availability of the MVC-COV1901 COVID-19 vaccine. This week, around 600,000 people are expected to receive the Medigen vaccine.
MVC gained Taiwan Emergency Use Authorization and approval in July to include MVC-COV1901 in Taiwan’s COVID-19 vaccine immunization programme. MVC COVID-19 vaccine is recommended for individuals over the age of 20 and is given in two doses 28 days apart for COVID-19 protection.MVC should produce a monthly safety control report during the stated EUA period, and a vaccination effectiveness report within one year of receiving EUA approval, according to the Advisory Committee.
Chen, Chief Executive Officer at Medigen stated,
Medigen is grateful for the opportunity to assist the Taiwanese people and contribute to the worldwide response to the pandemic. They were grateful to the Taiwan FDA for granting emergency use authorization, and they appreciate the time and effort put in by both the TFDA employees and the experts who attended the potential risks and benefits analysis meeting. It’s encouraging to see a positive outcome from the Medigen team’s tireless efforts.
Ryan Spencer, Chief Executive Officer of DVAX said,
They are glad to announce that Medigen’s vaccination is now available to Taiwanese citizens. They’re really thrilled for this first EUA and authorization for COVID-19 vaccines with CpG 1018 adjuvant, which they anticipate will be the start of many. They believe that adjuvanted vaccines can make a substantial contribution to existing vaccination efforts, despite the constraints of current vaccines and the worldwide vaccine deficit.